Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation

Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation

Isatuximab is an IgG1κ-derived monoclonal antibody against CD38 approved for the treatment of adult patients with multiple myeloma. Here we describe the successful treatment of a therapy-refractory pure red cell aplasia case following ABO-mismatched allogeneic stem cell transplantation with isatuxim...

Full description

Saved in:
Bibliographic Details
Main Authors: Mary Nauffal, Stephen Eng, Andrew Lin, Alexander Chan, Kathryn Mazzerella, Sergio Giralt, Miguel-Angel Perales, Boglarka Gyurkocza
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Case Reports in Hematology
Online Access:http://dx.doi.org/10.1155/2024/5790011
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items